ANI Common Stock vs Total Liab Analysis

ANIP Stock

USD 61.66 0.05 0.08%

ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Common Stock and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Common Stock vs Total Liab

Common Stock vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Common Stock account and Total Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between ANI Pharmaceuticals' Common Stock and Total Liab is -0.48. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Total Liab in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Common Stock and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of ANI Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Common Stock i.e., ANI Pharmaceuticals' Common Stock and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.48

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 05/23/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.

ANI Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables	Net Tangible Assets
Total Assets		0.95	0.84	1.0	0.9	0.7	0.16	0.94	0.6	0.95	0.6	-0.48	0.93	0.53	1.0	0.96	0.95	-0.48	0.98	0.97	-0.19	0.09	0.55	0.92	0.97	0.09
Other Current Liab	0.95		0.87	0.95	0.88	0.61	0.06	0.97	0.58	0.87	0.58	-0.38	0.84	0.61	0.94	0.95	0.93	-0.38	0.94	0.89	-0.24	-0.09	0.45	0.85	0.96	0.14
Total Current Liabilities	0.84	0.87		0.83	0.86	0.65	0.16	0.81	0.43	0.82	0.43	-0.37	0.77	0.48	0.85	0.85	0.77	-0.37	0.79	0.82	-0.06	-0.17	0.32	0.65	0.83	-0.09
Total Stockholder Equity	1.0	0.95	0.83		0.88	0.64	0.15	0.94	0.66	0.92	0.66	-0.48	0.93	0.56	0.98	0.95	0.96	-0.48	0.99	0.96	-0.15	0.12	0.6	0.92	0.95	0.15
Property Plant And Equipment Net	0.9	0.88	0.86	0.88		0.83	0.26	0.83	0.32	0.95	0.32	-0.48	0.79	0.43	0.92	0.94	0.76	-0.48	0.85	0.91	-0.26	-0.22	0.24	0.81	0.91	-0.09
Net Debt	0.7	0.61	0.65	0.64	0.83		0.32	0.56	-0.13	0.88	-0.13	-0.46	0.61	0.16	0.74	0.74	0.44	-0.46	0.62	0.74	-0.26	-0.11	0.13	0.66	0.75	-0.46
Retained Earnings	0.16	0.06	0.16	0.15	0.26	0.32		-0.06	-0.04	0.27	-0.04	-0.89	0.3	-0.01	0.17	0.08	0.04	-0.89	0.18	0.26	0.4	0.33	0.29	0.02	0.09	-0.18
Accounts Payable	0.94	0.97	0.81	0.94	0.83	0.56	-0.06		0.62	0.83	0.62	-0.31	0.8	0.65	0.93	0.96	0.94	-0.31	0.93	0.89	-0.38	-0.12	0.44	0.89	0.96	0.22
Cash	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62		0.34	1.0	-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.65	0.52	0.47	0.61
Non Current Assets Total	0.95	0.87	0.82	0.92	0.95	0.88	0.27	0.83	0.34		0.34	-0.52	0.86	0.39	0.96	0.93	0.79	-0.52	0.9	0.95	-0.19	0.03	0.42	0.87	0.93	-0.16
Cash And Short Term Investments	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62	1.0	0.34		-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.65	0.52	0.47	0.61
Common Stock Total Equity	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19		-0.57	-0.33	-0.48	-0.41	-0.39	1.0	-0.53	-0.58	-0.21	-0.33	-0.52	-0.39	-0.43	0.01
Common Stock Shares Outstanding	0.93	0.84	0.77	0.93	0.79	0.61	0.3	0.8	0.63	0.86	0.63	-0.57		0.46	0.91	0.82	0.89	-0.57	0.93	0.92	0.09	0.35	0.7	0.84	0.85	0.11
Other Current Assets	0.53	0.61	0.48	0.56	0.43	0.16	-0.01	0.65	0.46	0.39	0.46	-0.33	0.46		0.5	0.56	0.6	-0.33	0.62	0.61	-0.38	-0.16	0.54	0.59	0.56	0.14
Total Liab	1.0	0.94	0.85	0.98	0.92	0.74	0.17	0.93	0.55	0.96	0.55	-0.48	0.91	0.5		0.97	0.92	-0.48	0.97	0.97	-0.22	0.06	0.51	0.92	0.98	0.05
Property Plant And Equipment Gross	0.96	0.95	0.85	0.95	0.94	0.74	0.08	0.96	0.47	0.93	0.47	-0.41	0.82	0.56	0.97		0.89	-0.41	0.94	0.94	-0.34	-0.16	0.36	0.91	0.98	0.08
Total Current Assets	0.95	0.93	0.77	0.96	0.76	0.44	0.04	0.94	0.81	0.79	0.81	-0.39	0.89	0.6	0.92	0.89		-0.39	0.96	0.89	-0.17	0.14	0.62	0.87	0.9	0.34
Common Stock	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19	1.0	-0.57	-0.33	-0.48	-0.41	-0.39		-0.53	-0.58	-0.21	-0.33	-0.52	-0.39	-0.43	0.01
Other Stockholder Equity	0.98	0.94	0.79	0.99	0.85	0.62	0.18	0.93	0.65	0.9	0.65	-0.53	0.93	0.62	0.97	0.94	0.96	-0.53		0.97	-0.17	0.14	0.64	0.93	0.95	0.18
Short Long Term Debt Total	0.97	0.89	0.82	0.96	0.91	0.74	0.26	0.89	0.52	0.95	0.52	-0.58	0.92	0.61	0.97	0.94	0.89	-0.58	0.97		-0.2	0.09	0.59	0.92	0.94	0.01
Short Term Debt	-0.19	-0.24	-0.06	-0.15	-0.26	-0.26	0.4	-0.38	0.1	-0.19	0.1	-0.21	0.09	-0.38	-0.22	-0.34	-0.17	-0.21	-0.17	-0.2		0.57	0.21	-0.38	-0.34	0.12
Current Deferred Revenue	0.09	-0.09	-0.17	0.12	-0.22	-0.11	0.33	-0.12	0.35	0.03	0.35	-0.33	0.35	-0.16	0.06	-0.16	0.14	-0.33	0.14	0.09	0.57		0.7	0.07	-0.06	0.08
Non Currrent Assets Other	0.55	0.45	0.32	0.6	0.24	0.13	0.29	0.44	0.65	0.42	0.65	-0.52	0.7	0.54	0.51	0.36	0.62	-0.52	0.64	0.59	0.21	0.7		0.54	0.44	0.09
Non Current Liabilities Total	0.92	0.85	0.65	0.92	0.81	0.66	0.02	0.89	0.52	0.87	0.52	-0.39	0.84	0.59	0.92	0.91	0.87	-0.39	0.93	0.92	-0.38	0.07	0.54		0.92	0.1
Net Receivables	0.97	0.96	0.83	0.95	0.91	0.75	0.09	0.96	0.47	0.93	0.47	-0.43	0.85	0.56	0.98	0.98	0.9	-0.43	0.95	0.94	-0.34	-0.06	0.44	0.92		0.06
Net Tangible Assets	0.09	0.14	-0.09	0.15	-0.09	-0.46	-0.18	0.22	0.61	-0.16	0.61	0.01	0.11	0.14	0.05	0.08	0.34	0.01	0.18	0.01	0.12	0.08	0.09	0.1	0.06

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Liab	36.7M	54.0M	63.6M	69.3M	99.8M	104.8M
Total Current Liabilities	61.7M	78.6M	87.5M	99.4M	145.5M	152.8M
Total Stockholder Equity	212.8M	195.7M	358.7M	338.5M	432.7M	454.4M
Property Plant And Equipment Net	40.6M	41.3M	52.7M	43.2M	44.6M	46.8M
Net Debt	123.4M	177.8M	187.1M	238.3M	94.2M	98.9M
Retained Earnings	17.6M	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(84.1M)
Accounts Payable	14.6M	11.3M	23.0M	29.3M	36.7M	38.5M
Cash	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Non Current Assets Total	269.1M	290.9M	449.8M	415.8M	384.8M	404.0M
Cash And Short Term Investments	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Common Stock Shares Outstanding	12.0M	12.0M	12.6M	16.3M	18.2M	19.1M
Liabilities And Stockholders Equity	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Assets	5.1M	5.9M	11.3M	8.4M	25.2M	26.5M
Total Liab	244.0M	265.5M	412.9M	421.5M	471.7M	495.3M
Property Plant And Equipment Gross	40.6M	41.3M	75.6M	76.0M	77.5M	81.4M
Total Current Assets	187.7M	170.3M	321.8M	344.3M	519.6M	545.6M
Other Stockholder Equity	200.1M	212.1M	384.7M	398.8M	479.2M	503.1M
Accumulated Other Comprehensive Income	(4.9M)	(11.4M)	(3.1M)	12.2M	8.9M	9.3M
Short Long Term Debt Total	185.7M	185.7M	287.4M	286.5M	315.3M	331.1M
Short Term Debt	115.7M	9.9M	13.2M	850K	977.5K	928.6K
Current Deferred Revenue	451K	80K	87K	8.2M	9.4M	9.9M
Non Currrent Assets Other	1.2M	802K	2.2M	2.6M	6.1M	6.4M
Non Current Liabilities Total	182.3M	186.9M	325.3M	322.1M	326.2M	342.5M
Net Receivables	72.1M	95.8M	128.5M	165.4M	162.1M	170.2M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	175.8M	172.4M	286.5M	285.7M	284.8M	149.2M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	48.2M	60.8M	81.7M	105.4M	111.2M	116.8M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	180.4M	188.5M	294.1M	251.6M	209.0M	156.5M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M
Other Liab	7K	201K	31.0M	35.1M	40.3M	42.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:

How To Invest In ANI

Details

Is ANI Stock a good investment?

Details

What is ANI Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Transaction History View history of all your transactions and understand their impact on performance
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Stocks Directory Find actively traded stocks across global markets
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

13.824

Earnings Share

1.61

Revenue Per Share

27.705

Quarterly Revenue Growth

0.287

Return On Assets

0.0391

The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Common Stock vs Total Liab Analysis

Common Stock vs Total Liab

Common Stock vs Total Liab Correlation Analysis

Correlation Coefficient

Common Stock

Total Liab

ANI Pharmaceuticals fundamental ratios Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for ANI Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.98	Total Assets

Common Stock	- 0.89	Retained Earnings
Common Stock Total Equity	- 0.89	Retained Earnings
Short Long Term Debt Total	- 0.58	Common Stock
Short Long Term Debt Total	- 0.58	Common Stock Total Equity
Common Stock	- 0.57	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.57	Common Stock Total Equity